ClinicalTrials.gg
CompletedNCT04563871BLOSSOMUpdated Jul 28, 2026

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

A Phase 2 interventional study of 80mg Osimertinib in Non-small Cell Lung Cancer (NSCLC), sponsored by Sehhoon Park. Completed at 6 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Sehhoon Park · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
35th of 90
73 · median 51
Started
2020
with 7 others
Phase 2
46 of 90
12 open now
Registered
57th of 90
by date

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 35th largest by enrollment, is one of 8 that started in 2020, is one of 46 in phase 2, and was the 57th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This will be a Phase II, open-label, single-arm, multicenter study of the efficacy and safety of osimertinib (80 mg orally once daily) in patients with LM associated with EGFRm+ NSCLC.

Read the detailed description

The study will be conducted in approximately 5 sites across South Korea and will include EGFR TKI pre-treated patients. All patients will be required to have NSCLC associated with at least 1 site of LM as identified by the Investigator that can be assessed by magnetic resonance imaging (MRI) scan and that is suitable for repeat assessments. Presence of Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) measurable intracranial (INC) metastases (ie, brain parenchyma and cranial leptomeninges) and/or extracranial (EXC) metastases is not mandatory. The presence of LM will be based on the Investigator assessment of the brain MRI scan. LM will be confirmed by radiologist from the central site to ensure that patients enrolled in the study are assessable for LM radiologically. Patients negative for LM according to radiologist assessment but enrolled in the study will be replaced. The replaced patient will be included in the study and will receive investigational product (IP) if, in the opinion of the Investigator, the patient is able to receive clinical benefit. Such a patient will not be evaluable for LM response in the LM-EFR analysis set.Full analyses set (FAS) is defined as patients enrolled who received at least 1 dose of study treatment. In addition to Response Assessment in Neuro-Oncology criteria for Leptomeningeal Metastases (RANO-LM) assessments, separate RECIST 1.1 imaging assessments on EXC disease and INC (both LM and non-LM) disease will be performed on images acquired using the preferred method of contrast-enhanced computed tomography (CT) scan of the chest and abdomen (and pelvis when indicated) (EXC) and gadolinium contrast-enhanced MRI scan of the brain (INC).

Baseline scans will be acquired within 28 days prior to first dose of IP and then every 8 weeks (±1 week) and every 12 weeks (±1 week) after 12 months relative to first dose. Patients who discontinue IP for reasons other than objective disease progression in all of INC, EXC, and LM, will continue scans every 8 weeks (±1 week; relative to date of first dose of IP) and every 12 weeks (±1 week, after 12 months) until objective progression in INC, EXC, and LM or withdrawal of consent. Progression refers to progression assessed objectively by imaging using RECIST 1.1 for non-LM INC and EXC or RANO-LM criteria as appropriate. If a patient has been deemed to have LM subjective disease progression according to radiological and clinical assessment by the Investigatorstudy treatment can be continue, and the patient should maintain tumor imaging assessments according to the schedule of assessments.

CSF sampling for cytology is not mandatory, but is strongly encouraged, in patients who are willing to have lumbar punctures during the study, or in those patients who have Ommaya reservoirs.

Physical examination, Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status score, vital signs, and laboratory tests (hematology, clinical chemistry, and urinalysis) will be conducted at each visit. Adverse events (AEs) will be monitored and recorded on an ongoing basis. Twelve-lead electrocardiograms (ECGs) will be performed at baseline and at the time point of investigator's decision and will include measurement of the QT interval. A multigated acquisition scan (MUGA) or echocardiogram will be performed at baseline and at the time point of investigator's decision for left ventricular ejection fraction (LVEF) measurement. Plasma and CSF (if feasible) samples for pharmacokinetic (PK) analysis will be collected at pre-dose on Cycle 3 Day 1 and Cycle 6 Day 1.

Patient-Reported Outcome (PRO) questionnaires, including European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 items (EORTC QLQ-C30), EORTC Quality of Life Questionnaire-Brain Cancer Module 20 items (EORTC QLQ-BN20) will be collected at baseline (prior to first dose of IP and prior to all other assessments on Cycle 1 Day 1) and at home (every 8 weeks [±3 days for EORTC QLQ-C30 and EORTC QLQ-BN20 relative to administration of IP). The patient is asked to report PROs up to the end of Cycle 8 or to IP discontinuation, whichever comes first.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. Provision of signed and dated written ICF prior to any mandatory study specific procedures, sampling, and analyses.
  3. Male and female patients must be at least 18 years of age.
  4. Patients must have documented (only allowed for EGFRm+ [exon 19 deletions or L858R] in pre-treated patients) and/or confirmed central/local test result showing eligible EGFR mutation status as specified below:

    - EGFR TKI pre-treated patients: EGFRm+ (exon 19 deletions or L858R), along with valid T790M mutation status

  5. All patients will be required to have NSCLC associated with at least 1 site of LM as identified by the Investigator that can be assessed by MRI scan and that is suitable for repeat assessments. Measurable INC or EXC disease by 1.1 is not required. Concomitant and brain metastases previously treated with radiation therapy are allowed. In addition, asymptomatic untreated BM is also allowed.
  6. EGFR TKI pre-treated patients must have had at least 1 prior EGFR TKI (eg, gefitinib, erlotinib, icotinib, dacomitinib or afatinib) and may have had other
  7. If the patients is T790M negative, EXC must be stable following previous EGFR TKI treatment. EXC progression is allowed if patients are T790M positive patients
  8. performance status 0 to 2 with no deterioration over the previous 2 weeks and a minimum of 12 weeks.
  9. Females must be using highly effective measures and must have a negative pregnancy test prior to start of dosing if of , or must have evidence of non-childbearing potential by fulfilling one of the following criteria at screening:

    • , defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments
    • Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution
    • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation Further information is in Appendix I (Definition of women of childbearing potential and acceptable contraceptive methods).
  10. Male patients must be willing to use barrier contraception
  11. For inclusion in the optional genetics research study, patients must provide informed consent for genetic research.
  12. If a patient declines to participate in any voluntary exploratory research of the study, there will be no penalty or loss of benefit to the patient and he/she will not be excluded from other aspects of the study.

Exclusion criteria

Exclusion Criteria:

  1. EGFR TKI pre-treated patients whose T790M mutation status cannot be determined.
  2. EGFR TKI pre-treated patients with progressing EXC disease who are T790M mutation-negative. Progressing EXC disease is defined as 1.1 PD no more than 3 months prior to enrollment, per Investigator assessment.
  3. Past medical history of ILD, drug-induced ILD, radiation pneumonitis that required treatment, or any evidence of clinically active ILD.
  4. Significant medical or psychiatric illness that would interfere with compliance and ability to tolerate treatment as outlined in the protocol.
  5. Any of the following cardiac criteria:

    • Mean resting corrected >470 msec, obtained from ECGs, using the screening clinic machine-derived QTc value
    • Any abnormalities in rhythm, conduction, or morphology of resting ECG (eg, complete left bundle branch block, third degree heart block, and second degree heart block)
    • Patients with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as the following electrolyte abnormalities, heart failure, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP):

      • Hypokalemia (serum potassium \<3.5 mmol/L)
      • Hypomagnesemia (serum magnesium \<0.7 mmol/L)
      • Hypocalcemia (corrected serum calcium \<2.1 mmol/L)
  6. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    • \<1.5×109/L
    • count \<100×109/L
    • \<90 g/L
    • (ALT) >2.5× the (ULN) if no demonstrable liver or >5× ULN in the presence of liver metastases
    • Aspartate aminotransferase (AST) >2.5× ULN if no demonstrable liver metastases or >5× ULN in the presence of liver metastases
    • Total (TBL) >1.5× ULN if no liver metastases or >3× ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases
    • Creatinine >1.5× ULN concurrent with \<50 mL/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is >1.5× ULN
  7. Known INC hemorrhage that is unrelated to tumor.
  8. Patients with the clinical manifestation of nervous system failure including severe encephalopathy or with severe nervous system injury related with treatment, such as chemical meningitis.
  9. Non-malignant neurological disease that would interfere with evaluation of symptoms or signs of LM.
  10. CNS complications that require urgent neurosurgical intervention (eg, resection or shunt placement) up to 2 weeks before to start of IP or patients who have not recovered from side effects of such intervention.
  11. Treatment with any of the following:

    • Any cytotoxic chemotherapy, agents, or anticancer drugs (other than EGFR TKI) for the treatment of advanced NSCLC from a previous treatment regimen or clinical study up to 14 days before the first dose of IP.
    • Treatment with an EGFR TKI (eg, afatinib, erlotinib, icotinib, dacomitinib or gefitinib) up to 8 days or approximately 5× half-life, whichever is the longer, before the first dose of IP (if sufficient time has not occurred due to schedule or PK properties, an alternative appropriate wash-out time based on known duration and time to reversibility of drug-related AEs could be agreed upon by principal investigator).
    • Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP) 3A4 (at least 3 weeks prior) (see Appendix H). All patients must try to avoid concomitant use of any medications, herbal supplements, and/or ingestion of foods with known inducer effects on .
    • Any unresolved toxicities from prior therapy greater than Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy.
    • Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol, or active infection including , , and . Screening for chronic conditions is not required.
    • nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.
    • Major surgery (excluding placement of vascular access) up to 4 weeks before the first dose of IP.
    • Radiotherapy, as specified, during the following windows:

      • Radiotherapy with a wide field of radiation (including whole brain radiotherapy) up to 2 weeks before the first dose of IP
      • Radiotherapy with a limited field of radiation for palliation up to 1 week before the first dose of IP except for patients receiving radiation to more than 30% of the bone marrow, which must be completed up to 2 weeks before the first dose of IP.
    • Patients receiving intrathecal chemotherapy up to 2 weeks before the first dose of IP.
    • Previously treated with osimertinib.
    • Any requirement for concurrent therapy including radiotherapy for LM other than the specified treatment in this study.
    • Use of corticosteroid to control increased intracranial pressure is allowed
  12. History of to active or inactive of osimertinib or drugs with a similar chemical structure or class to osimertinib.
  13. Patient with involvement in the planning and/or conduct of the study (applies to both principal investigator and/or staff at the study site).
  14. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  15. Patient has previously participated in the present study, except for rescreened patients with T790M mutation-negative disease who were previously screened but were excluded due to progressing EXC disease that has subsequently been stabilized.
  16. For female patients only - Women who are breastfeeding or currently pregnant (confirmed with positive pregnancy test).
  17. to MRI, including, but not limited to, claustrophobia, pacemakers, metal implants, INC surgical clips, and metal foreign bodies.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    80mg Osimertinib

    One tablet of 80mg Osimertinib for oral administration per day

    Drug: 80mg Osimertinib

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival

    To investigate the efficacy of osimertinib on LM as measured by OS

    Time frame: Up to 30 months

Secondary outcomes

  1. LM ORR(Objective response rate)

    BICR(Blinded independent central review) assessments, based on neuroimaging RANO-LM

    Time frame: Up to 30 months

  2. LM DoR(Duration of response)

    BICR(Blinded independent central review) assessments, based on neuroimaging RANO-LM

    Time frame: Up to 30 months

  3. LM DCR(Disease control rate)

    BICR(Blinded independent central review) assessments, based on neuroimaging RANO-LM

    Time frame: Up to 30 months

  4. LM PFS(Progression-free survival)

    BICR(Blinded independent central review) assessments, based on neuroimaging RANO-LM

    Time frame: Up to 30 months

  5. CSF response rate based on CSF cytology

    To investigate the efficacy of osimertinib in patients with LM associated with EGFRm+ NSCLC on the CSF cytological clearance

    Time frame: Up to 30 months

07

Study locations

6 sites
  • ChungBuk National University Hospital
    Cheonju, South Korea
  • National Cancer Center
    Goyang, South Korea
  • Seoul National University Bundang Hospital
    Seongnam, South Korea
  • Samsung Medical Center
    Seoul, 135-710, South Korea
  • Asan Medical Center
    Seoul, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
08

References and documents

Publications

  • Park S, Baldry R, Jung HA, Sun JM, Lee SH, Ahn JS, Kim YJ, Lee Y, Kim DW, Kim SW, Lee KH, Lee WJ, Choi JW, Chong K, Lee JI, Gwon SH, Son NH, Ahn MJ. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM). J Clin Oncol. 2024 Aug 10;42(23):2747-2756. doi: 10.1200/JCO.24.00708. Epub 2024 Jun 3. PubMed 38828959 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Oct 2023, 35 months.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 35 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2020
First posted
Sep 25, 2020
StartActual
Nov 17, 2020
Primary completionActual
Oct 25, 2023
CompletionActual
Oct 25, 2023
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04563871
Lead sponsor
Sehhoon Park
Collaborators
AstraZeneca
Responsible party
Sehhoon Park (Coordinating investigator, Samsung Medical Center) — Sponsor-investigator
First posted
Sep 25, 2020
Start date
Nov 17, 2020
Primary completion
Oct 25, 2023
Completion
Oct 25, 2023
Last update
Jul 28, 2026

Study contacts

Se-Hoon Lee, M.D, Ph.D.
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion